Immunotargeting: A biological approach to the treatment of psoriasis

Autor:	B. S. Baker, L. Fry
Rok vydání:	2007
Předmět:	Pharmacology medicine.medical_specialty business.industry medicine.medical_treatment T cell T lymphocyte medicine.disease Dermatology Infliximab Alefacept Psoriatic arthritis Cytokine medicine.anatomical_structure Psoriasis Drug Discovery Immunology Adalimumab Molecular Medicine Medicine business medicine.drug
Zdroj:	Drug Discovery Today: Therapeutic Strategies. 4:201-207
ISSN:	1740-6773
Popis:	Biological therapies targeting T cell activation and trafficking, and the cytokine TNF-α have recently been approved for use in psoriasis and/or psoriatic arthritis. Clinical evidence suggests that they are both safe and efficacious for moderate to severe psoriasis and suitable for relatively long-term use. Causes for concern include T lymphocyte depletion (alefacept) and reactivation of mycobacterial infections (infliximab and adalimumab). Biological agents against further immunotargets, such as the Th-1 differentiating cytokines IL-12 and IL-23, are being developed.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::07940a8a39210899787dc850de03adb8 https://doi.org/10.1016/j.ddstr.2007.11.002 Zobrazit plný text záznamu Full Text from ScienceDirect